6-Deoxyerythronolide B

Identification

Generic Name
6-Deoxyerythronolide B
DrugBank Accession Number
DB04070
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 386.5228
Monoisotopic: 386.266838948
Chemical Formula
C21H38O6
Synonyms
Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
U6-deoxyerythronolide B hydroxylaseNot AvailableSaccharopolyspora erythraea (strain NRRL 23338)
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with 6-Deoxyerythronolide B.
AcalabrutinibThe serum concentration of Acalabrutinib can be increased when it is combined with 6-Deoxyerythronolide B.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with 6-Deoxyerythronolide B.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with 6-Deoxyerythronolide B.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with 6-Deoxyerythronolide B.
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as macrolides and analogues. These are organic compounds containing a lactone ring of at least twelve members.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Macrolides and analogues
Sub Class
Not Available
Direct Parent
Macrolides and analogues
Alternative Parents
Secondary alcohols / Lactones / Cyclic ketones / Carboxylic acid esters / Polyols / Oxacyclic compounds / Monocarboxylic acids and derivatives / Organic oxides / Hydrocarbon derivatives
Substituents
Alcohol / Aliphatic heteromonocyclic compound / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Cyclic ketone / Hydrocarbon derivative / Ketone / Lactone / Macrolide
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
erythronolide (CHEBI:16089) / Macrolides and lactone polyketides (C03240) / Macrolides and lactone polyketides (LMPK04000002)
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available
InChI Key
HQZOLNNEQAKEHT-IBBGRPSASA-N
InChI
InChI=1S/C21H38O6/c1-8-16-12(4)19(24)13(5)17(22)10(2)9-11(3)18(23)14(6)20(25)15(7)21(26)27-16/h10-16,18-20,23-25H,8-9H2,1-7H3/t10-,11+,12+,13+,14-,15-,16-,18+,19+,20+/m1/s1
IUPAC Name
(3R,4S,5R,6S,7S,9R,11R,12S,13R,14R)-14-ethyl-4,6,12-trihydroxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione
SMILES
[H][C@@]1(C)C[C@]([H])(C)[C@]([H])(O)[C@@]([H])(C)[C@]([H])(O)[C@@]([H])(C)C(=O)O[C@]([H])(CC)[C@]([H])(C)[C@]([H])(O)[C@@]([H])(C)C1=O

References

Synthesis Reference

Robert McDaniel, "Production of 8,8a-dihydroxy-6-deoxyerythronolide B." U.S. Patent US20010034046, issued October 25, 2001.

US20010034046
General References
Not Available
KEGG Compound
C03240
PubChem Compound
121904
PubChem Substance
46508714
ChemSpider
108752
ChEBI
16089
ZINC
ZINC000004096057
PDBe Ligand
DEB
PDB Entries
1jio / 1oxa / 1z8o / 1z8p / 1z8q / 5mns / 5mnv / 6zi3 / 7q6r / 7q6x
show 1 more

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.12 mg/mLALOGPS
logP1.8ALOGPS
logP2.87Chemaxon
logS-2.5ALOGPS
pKa (Strongest Acidic)14Chemaxon
pKa (Strongest Basic)-3Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area104.06 Å2Chemaxon
Rotatable Bond Count1Chemaxon
Refractivity102.94 m3·mol-1Chemaxon
Polarizability42.94 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.8891
Blood Brain Barrier+0.8618
Caco-2 permeable-0.5356
P-glycoprotein substrateSubstrate0.5407
P-glycoprotein inhibitor INon-inhibitor0.8554
P-glycoprotein inhibitor IINon-inhibitor0.7101
Renal organic cation transporterNon-inhibitor0.9497
CYP450 2C9 substrateNon-substrate0.8196
CYP450 2D6 substrateNon-substrate0.8539
CYP450 3A4 substrateNon-substrate0.5317
CYP450 1A2 substrateNon-inhibitor0.8867
CYP450 2C9 inhibitorNon-inhibitor0.8888
CYP450 2D6 inhibitorNon-inhibitor0.9394
CYP450 2C19 inhibitorNon-inhibitor0.8459
CYP450 3A4 inhibitorNon-inhibitor0.5415
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9514
Ames testNon AMES toxic0.6607
CarcinogenicityNon-carcinogens0.8856
BiodegradationNot ready biodegradable0.8668
Rat acute toxicity2.6539 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9771
hERG inhibition (predictor II)Non-inhibitor0.9444
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0v4r-1009000000-e12a3871e574e7be5ad8
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0gb9-0009000000-b7bd7cef7d1068b28dee
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0gb9-0009000000-bd5d9f5610c28617360e
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-0009000000-27d364195945d23955e2
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-0009000000-85f8b8f497f42c573f5e
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-0009000000-c53548a24a4b30eb14e3
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-014r-0009000000-cb0c4349f5128a55c667
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-202.370514
predicted
DarkChem Lite v0.1.0
[M-H]-178.4115
predicted
DeepCCS 1.0 (2019)
[M+H]+203.621514
predicted
DarkChem Lite v0.1.0
[M+H]+180.4107
predicted
DeepCCS 1.0 (2019)
[M+Na]+202.618514
predicted
DarkChem Lite v0.1.0
[M+Na]+186.6477
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Saccharopolyspora erythraea (strain NRRL 23338)
Pharmacological action
Unknown
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen
Specific Function
Catalyzes the NADPH-dependent conversion of 6-deoxyerythronolide B (6-DEB) to erythronolide B (EB) by the insertion of an oxygen at the 6S position of 6-DEB. Requires the participation of a ferredo...
Gene Name
eryF
Uniprot ID
Q00441
Uniprot Name
6-deoxyerythronolide B hydroxylase
Molecular Weight
45098.685 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. doi: 10.2165/00003088-200039030-00003. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52